Clinical Trial Update: Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating immunological and histological responses to a recombinant hypoallergenic derivative immunotherapy for allergic rhinoconjunctivitis ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• Recombinant hypoallergenic derivative immunotherapy

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Allergic Rhinoconjunctivitis | Phase 2 | Status: COMPLETED